These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 22628411)

  • 1. A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma.
    Collisson EA; Trejo CL; Silva JM; Gu S; Korkola JE; Heiser LM; Charles RP; Rabinovich BA; Hann B; Dankort D; Spellman PT; Phillips WA; Gray JW; McMahon M
    Cancer Discov; 2012 Aug; 2(8):685-93. PubMed ID: 22628411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RAF/MEK dependence of KRAS-mutant pancreatic ductal adenocarcinomas.
    Hanrahan AJ; Solit DB
    Cancer Discov; 2012 Aug; 2(8):666-9. PubMed ID: 22886659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling.
    Appleman VA; Ahronian LG; Cai J; Klimstra DS; Lewis BC
    Mol Cancer Res; 2012 Sep; 10(9):1228-39. PubMed ID: 22871572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of mRNA profiles after MEK1/2 inhibition in human pancreatic cancer cell lines reveals pathways involved in drug sensitivity.
    Gysin S; Paquette J; McMahon M
    Mol Cancer Res; 2012 Dec; 10(12):1607-19. PubMed ID: 22833572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers.
    Kinsey CG; Camolotto SA; Boespflug AM; Guillen KP; Foth M; Truong A; Schuman SS; Shea JE; Seipp MT; Yap JT; Burrell LD; Lum DH; Whisenant JR; Gilcrease GW; Cavalieri CC; Rehbein KM; Cutler SL; Affolter KE; Welm AL; Welm BE; Scaife CL; Snyder EL; McMahon M
    Nat Med; 2019 Apr; 25(4):620-627. PubMed ID: 30833748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of the RAF/MEK/ERK Signaling Cascade in Pancreatic Cancer: Recent Advances and Future Perspectives.
    Adamopoulos C; Cave DD; Papavassiliou AG
    Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells.
    Ji Z; Mei FC; Xie J; Cheng X
    J Biol Chem; 2007 May; 282(19):14048-55. PubMed ID: 17353198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationships among
    Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
    World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
    Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
    J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
    Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
    Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.
    Joseph EW; Pratilas CA; Poulikakos PI; Tadi M; Wang W; Taylor BS; Halilovic E; Persaud Y; Xing F; Viale A; Tsai J; Chapman PB; Bollag G; Solit DB; Rosen N
    Proc Natl Acad Sci U S A; 2010 Aug; 107(33):14903-8. PubMed ID: 20668238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
    Poulikakos PI; Zhang C; Bollag G; Shokat KM; Rosen N
    Nature; 2010 Mar; 464(7287):427-30. PubMed ID: 20179705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maintenance of acinar cell organization is critical to preventing Kras-induced acinar-ductal metaplasia.
    Shi G; DiRenzo D; Qu C; Barney D; Miley D; Konieczny SF
    Oncogene; 2013 Apr; 32(15):1950-8. PubMed ID: 22665051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1.
    Gysin S; Lee SH; Dean NM; McMahon M
    Cancer Res; 2005 Jun; 65(11):4870-80. PubMed ID: 15930308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.
    Hoeflich KP; Herter S; Tien J; Wong L; Berry L; Chan J; O'Brien C; Modrusan Z; Seshagiri S; Lackner M; Stern H; Choo E; Murray L; Friedman LS; Belvin M
    Cancer Res; 2009 Apr; 69(7):3042-51. PubMed ID: 19276360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers.
    Ozkan-Dagliyan I; Diehl JN; George SD; Schaefer A; Papke B; Klotz-Noack K; Waters AM; Goodwin CM; Gautam P; Pierobon M; Peng S; Gilbert TSK; Lin KH; Dagliyan O; Wennerberg K; Petricoin EF; Tran NL; Bhagwat SV; Tiu RV; Peng SB; Herring LE; Graves LM; Sers C; Wood KC; Cox AD; Der CJ
    Cell Rep; 2020 Jun; 31(11):107764. PubMed ID: 32553168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
    Hatzivassiliou G; Song K; Yen I; Brandhuber BJ; Anderson DJ; Alvarado R; Ludlam MJ; Stokoe D; Gloor SL; Vigers G; Morales T; Aliagas I; Liu B; Sideris S; Hoeflich KP; Jaiswal BS; Seshagiri S; Koeppen H; Belvin M; Friedman LS; Malek S
    Nature; 2010 Mar; 464(7287):431-5. PubMed ID: 20130576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.
    Halilovic E; She QB; Ye Q; Pagliarini R; Sellers WR; Solit DB; Rosen N
    Cancer Res; 2010 Sep; 70(17):6804-14. PubMed ID: 20699365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the prohibitin scaffold-CRAF kinase interaction in RAS-ERK-driven pancreatic ductal adenocarcinoma.
    Luan Z; He Y; Alattar M; Chen Z; He F
    Mol Cancer; 2014 Feb; 13():38. PubMed ID: 24568222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of mutant KrasG12D-initiated murine pancreatic carcinoma growth by a dual c-Raf and soluble epoxide hydrolase inhibitor t-CUPM.
    Liao J; Hwang SH; Li H; Yang Y; Yang J; Wecksler AT; Liu JY; Hammock BD; Yang GY
    Cancer Lett; 2016 Feb; 371(2):187-93. PubMed ID: 26683769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.